Diagnostic accuracy of cerebrospinal fluid biomarkers for the differential diagnosis of sporadic Creutzfeldt–Jakob disease: a (network) meta‐analysis
Authors:
Open Access
- 24 January 2022
- journal article
- research article
- Published by Wiley in European Journal of Neurology
- Vol. 29 (5) , 1366-1376
Abstract
Background: There are no systematic reviews of cerebrospinal fluid and blood biomarkers for sporadic Creutzfeldt–Jakob disease (sCJD) in specialized care settings that compare diagnostic accuracies in a network meta‐analysis (NMA).Methods: We searched Medline, Embase, and Cochrane Library for diagnostic studies of sCJD biomarkers. Studies had to use established diagnostic criteria for sCJD and for diseases in the non‐CJD groups, which had to represent a consecutive population of patients suspected as a CJD case, as reference standard. Risk of bias was assessed with QUADAS‐2. We conducted individual biomarker meta‐analyses with generalized bivariate models. To investigate heterogeneity, we performed subgroup analyses based on QUADAS‐2 quality and clinical criteria. For the NMA, we applied a Bayesian beta‐binomial ANOVA model. The study protocol was registered at PROSPERO (CRD42019118830).Results: Of 2976 publications screened, we included 16 studies, which investigated 14–3‐3β (n = 13), 14–3‐3γ (n = 3), neurofilament light chain (NfL, n = 1), neuron‐specific enolase (n = 1), p‐tau181/t‐tau ratio (n = 2), RT‐QuIC (n = 7), S100B (n = 3), t‐tau (n = 12), and t‐tau/Aβ42 ratio (n = 1). Excluded diagnostic studies had strong limitations in study design. In the NMA, RT‐QuIC (0.91; 95% CI [0.83, 0.95]) and NfL (0.93 [0.78, 0.99]) were the most sensitive biomarkers for the diagnosis of definite, probable, and possible sCJD cases. RT‐QuIC was the most specific biomarker (0.97 [0.89, 1.00]). Heterogeneity in accuracy estimates was high between studies.Conclusions: We identified RT‐QuIC as the most accurate biomarker, partially confirming currently applied diagnostic criteria. The shortcomings identified in many diagnostic studies for sCJD biomarkers need to be addressed in future studies.Keywords
All Related Versions
This publication has 42 references indexed in Scilit:
- Evidence-based guideline: Diagnostic accuracy of CSF 14-3-3 protein in sporadic Creutzfeldt-Jakob diseaseNeurology, 2012
- QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy StudiesAnnals of Internal Medicine, 2011
- The role of cerebrospinal fluid 14-3-3 and other proteins in the diagnosis of sporadic Creutzfeldt-Jakob disease in the UK: a 10-year reviewJournal of Neurology, Neurosurgery & Psychiatry, 2010
- Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob diseaseBrain, 2009
- Creutzfeldt-Jakob disease in Germany: a prospective 12-year surveillanceBrain, 2007
- Bivariate meta-analysis of sensitivity and specificity with sparse data: a generalized linear mixed model approachJournal of Clinical Epidemiology, 2006
- Evidence of bias and variation in diagnostic accuracy studiesCanadian Medical Association Journal, 2006
- The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessedJournal of Clinical Epidemiology, 2005
- A prospective study of CSF markers in 250 patients with possible Creutzfeldt-Jakob diseaseJournal of Neurology, Neurosurgery & Psychiatry, 2003
- Detection of 14‐3‐3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt‐Jakob diseaseAnnals of Neurology, 1998